NMN - Nicotinamide Mononucleotide

Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism

Nicotinamide Mononucleotide Research

The World Health Organization (WHO) released its ‘International Classification of Diseases’ in June 2018, recognising ageing as a disease for the first time.

This recognition follows the research into the field of longevity, which looks to find cures for the ageing process in the hope of increasing human lifespan and health span. One of the most promising molecules is nicotinamide mononucleotide (NMN), whose levels decline as we age.

The paper below is a review article published in Frontiers in Cell and Developmental Biology in April 2020.

The paper discusses NMN research in relation to diabetes, obesity, heart failure & cardiomyopathies, vascular dysfunction, intracerebral haemorrhage, neuroprotective & cognitive decline, Alzheimer’s, retinal degeneration & corneal injury, acute kidney injury, and alcoholic liver disease.

To read a research paper published in December 2022 on the effects of NMN on 80 middle-aged adults, click here.